Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781323 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
A Phase 2 study of Advanced Rectal Cancer, sponsored by University of Rochester.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT03781323 is a Phase 2 study of Advanced Rectal Cancer that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 12 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT03781323, a Phase 2 study of Advanced Rectal Cancer, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the treatment of patients with locally advanced rectal cancer for complete response to neoadjuvant chemotherapy without the use of radiation and surgery.
Conditions Studied
Interventions
- DRUG FOLFOX
Study Locations (2)
New York
- University of Rochester, James P. Wilmot Cancer Center - Rochester
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781323
The ClinicalTrials.gov registry entry for NCT03781323 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which FOLFOX is the first listed.
NCT03781323 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03781323 about?
NCT03781323 is a clinical study titled "Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer". The purpose of this study is to evaluate the treatment of patients with locally advanced rectal cancer for complete response to neoadjuvant chemotherapy without the use of radiation and surgery.
What is the current status of trial NCT03781323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-05-03. Estimated completion is 2027-06-01.
What conditions does trial NCT03781323 study?
This clinical trial studies the following conditions: Advanced Rectal Cancer.
What interventions are being tested in trial NCT03781323?
The interventions under investigation include: FOLFOX (DRUG).
Who is sponsoring clinical trial NCT03781323?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03781323 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.